The CRESLA, which has a diagnostic neuropathology laboratory and a molecular genetics laboratory, is clinically based in the “Città della Salute e della Scienza” of Torino, the largest public hospital in Italy.
In the last decade, the CRESLA has participated to 5 large international randomized clinical trials on innovative drugs in ALS. The center is able to design and carry on both phase I-II and phase II trials, and includes a data manager and a statistical branch.
The centre has a multidisclinary group, with a daily ALS clinic, and utilizes the in-patient beds and the day hospital of the Department of Neuroscience. The centre includes a psychological and neuropsychological service. The centre has a neurophysiological service (EMG, motor evoked potentials) and collaborates with the Laboratory of Neuropathology and Neurobiology (located in the same Department) and the Laboratory of Molecular Biology and Genetics (located in a nearby hospital).
Adriano ChiòProfessor of Neurology
Adriano Chiò is professor of Neurology at the University of Torino, Italy
TUDCA (tauroursodeoxycholic acid) is a small molecule that is being explored for its potential as a treatment for ALSRead more
PreLude (Lithium carbonate)
Within an innovative platform design study, we will evaluate the efficacy of lithium carbonate in UNC13a homozygous patients.Read more
Within an innovative platform design study, we will evaluate the efficacy of Triumeq, a therapy developed for treatment of HIV that has shown to slow progression in ALSRead more
iAdore (Oral edaravone)
Within an innovative platform design study, we will evaluate the efficacy of oral edaravone (TW001), a formulation that reduces oxidative stressRead more